Sai Parenterals Limited — PPTs, 12-08-2026: Investor Presentation

Here's a summary of Sai Parenterals Limited's investor presentation, focusing on key insights for retail investors:

**1. Business Performance:**

Sai Parenterals has seen robust growth, with consolidated revenue jumping significantly. The CDMO (Contract Development and Manufacturing Organization) segment, driven by long-term contracts, has been a key growth driver. Exports have also expanded substantially, now forming a significant portion of revenue, with Australia and the Philippines being major contributors.

**2. Growth Drivers or Strategy:**

The company is focusing on expanding its manufacturing capacity, particularly for injectables, through a new facility and strategic acquisitions. Enhancing R&D capabilities, including complex injectables and oncology, is another core strategy. Leveraging its strong dossier library and regulatory approvals is crucial for tapping into global markets.

**3. Recent Developments:**

Key developments include a proposed variation in the utilization of IPO proceeds to invest in Saicriti Pharma (for a new injectable facility) and Prathyak Laboratories (for an R&D center). Funding for the Australian facility is complete, with manufacturing expected to start soon. The company is also evaluating entry into the US market.

**4. Key Financial Metrics:**

Consolidated revenue saw a substantial year-on-year increase of over 400% in Q1FY27. EBITDA and PAT margins have also shown significant improvement, reflecting better operational efficiency and pricing benefits.

**5. Management Commentary / Outlook:**

Management expects FY27 revenue of Rs. 750 crore with an EBITDA margin of around 17%. Growth is anticipated to be weighted towards the second half of the year, supported by contract price revisions, the commissioning of the Australian facility, and the expected revenue acceleration from new R&D and manufacturing capabilities. The company is focused on capital discipline and leveraging its investments for future growth.